Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541720 · ClinicalTrials.gov registry record · Early Phase 1
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
A Early Phase 1 study of Neuroblastoma and Pheochromocytoma, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03541720: Active Early Phase 1 study of Neuroblastoma and Pheochromocytoma, sponsored by St. Jude Children's Research Hospital.
NCT03541720 is a Early Phase 1 study of Neuroblastoma and Pheochromocytoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 13 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03541720, a Early Phase 1 study of Neuroblastoma and Pheochromocytoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
PET (positron emission tomography) scans combined with a radioactive tracer will be used to identify and analyze tumors. Currently, the most common tracer used to analyze neuroblastoma tumors is called 123I-mIBG. However, the picture it provides is not always clear enough to see the very small areas of the disease. 18F-DA (18F-fluorodopamine) has been shown to be safe and more effective than 123I-mIBG in analyzing the tumor pheochromocytoma, which is closely related to neuroblastoma. With this research study, the investigators plan to meet the following goals: * Investigate to see if 18F-DA is safe to administer to pediatric patients with known or suspected neuroblastoma or pheochromocytoma * Examine where in the body 18F-DA goes. * Obtain information comparing 18F-DA to 123I-mIBG to see if 18F-DA could replace 123I-mIBG in the future. About 20 people, with known or suspected neuroblastoma or pheochromocytoma, will take part in this Pilot study at St. Jude.
Primary Outcome
The adverse events will be recorded and monitored up to two days after the injection of radiotracer 18F-DA. The 95% CI for the adverse event rate will be calculated and reported. If one adverse event grade 2 or above, attributable to study drug, the study will be stopped until completion of IRB review and a decision about whether the study should be modified or closed.
Conditions Studied
Interventions
- DRUG 18F-DA
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2028-07-01 |
| Phase | Early Phase 1 |
What the registry record for NCT03541720 still lists
NCT03541720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which 18F-DA is the first listed.
NCT03541720 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03541720 about?
NCT03541720 is a clinical study titled "18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma". PET (positron emission tomography) scans combined with a radioactive tracer will be used to identify and analyze tumors. Currently, the most common tracer used to analyze neuroblastoma tumors is called 123I-mIBG. However, the picture it provides is not always clear enough to see the very small areas...
What is the current status of trial NCT03541720?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2019-04-30. Estimated completion is 2028-07-01.
What conditions does trial NCT03541720 study?
This clinical trial studies the following conditions: Neuroblastoma, Pheochromocytoma.
What interventions are being tested in trial NCT03541720?
The interventions under investigation include: 18F-DA (DRUG).
Who is sponsoring clinical trial NCT03541720?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03541720 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03541720's enrollment target sits among peer trials
13 84th of 94 higher than 9 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of N9 Chemotherapy in Children With Neuroblastoma
ACTIVE NOT RECRUITING · Early Phase 1
-
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
COMPLETED · Early Phase 1
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI